by Dr. Patrizia Carlevaro, Head of International Aid Unit, Eli Lilly and Company, Geneva IFPMA Geneva Pharma Forum on 24 November 2009
Read moreby Dr. Patrizia Carlevaro, Head of International Aid Unit, Eli Lilly and Company, Geneva IFPMA Geneva Pharma Forum on 24 November 2009
Read moreby Dr. Brendan Barnes, Director, Multilateral Issues & Health Policy, EFPIA, Brussels IFPMA Geneva Pharma Forum on 24 November 2009
Read moreby Dr. Brendan Barnes, Director, Multilateral Issues & Health Policy, EFPIA, Brussels IFPMA Geneva Pharma Forum on 24 November 2009
Read moreby Dr. Brendan Barnes, Director, Multilateral Issues & Health Policy, EFPIA, Brussels IFPMA Geneva Pharma Forum on 24 November 2009
Read moreby Dr. Alan Oxley, Chairman APEC Centre, RMIT University, Melbourne IFPMA Geneva Pharma Forum on 24 November 2009
Read moreby Dr. Alan Oxley, Chairman APEC Centre, RMIT University, Melbourne IFPMA Geneva Pharma Forum on 24 November 2009
Read moreby Mr. Thaddeus Burns Senior Counsel, IP & Trade, General Electric
Read moreby Mr. Thaddeus Burns Senior Counsel, IP & Trade, General Electric
Read moreby Dr. Markus Boehringer, Vicedirector, Section Head Metabolic Diseases, Hoffmann — La Roche, Basel IFPMA Geneva Pharma Forum on 24 November 2009
Read moreby Dr. Markus Boehringer, Vicedirector, Section Head Metabolic Diseases, Hoffmann — La Roche, Basel IFPMA Geneva Pharma Forum on 24 November 2009
Read moreby Prof. Wim Vanhaverbeke Hasselt University (Belgium), ESADE Business School (Spain) [Side Event at WIPO General Assemblies on 22nd September 2010]
Read more